InVirtuoLabs

Name

InVirtuoLabs

Legal name

InVirtuoLabs SA

Website

https://invirtuolabs.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• AI drug discovery
• Generative chemistry
• Molecular simulations
• Computational drug design
• Pharmaceutical AI platform

Headquarters

HQ city

Lugano

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. AI Platform Licensing & Co-Development: Revenue generated through strategic R&D collaborations with pharmaceutical companies where InVirtuoLabs applies its AI platform to design, optimize, and prioritize drug candidates. Partners like Helsinn provide proprietary compound libraries while InVirtuoLabs delivers optimized lead compounds for preclinical development.
2. Eurostars Research Grant: Non-dilutive funding from €2.3M Eurostars grant for NEUROSPARK project targeting rare neurodegenerative disorders, with potential expansion to Alzheimer's and Parkinson's treatments.
3. EuroHPC Access Grant: EuroHPC JU AI Large Scale Access grant providing 2,000,000 GPU-hours (worth ~€3M) on LUMI-G supercomputer for MASH liver disease research.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

InVirtuoLabs builds and operates the InVirtuo Platform, an AI-powered end-to-end drug discovery system that combines multimodal learning, active learning, and generative chemistry with physics-based molecular simulations. The platform is delivered as three integrated modules — InVirtuoMOL (molecular property evaluation ML engine), InVirtuoGEN (multimodal generative AI for novel molecule design, capable of generating 1 billion molecules per day), and InVirtuoSIM (physics-based modeling of drug-target interactions) — applied through co-development partnerships with pharmaceutical and biotech companies to identify and optimize preclinical drug candidates.

Product overview

InVirtuoLabs offers a modular AI-powered drug discovery platform called the InVirtuo Platform, which integrates three core modules: InVirtuoMOL (molecular ML engine for property evaluation), InVirtuoGEN (multimodal generative AI for molecule design), and InVirtuoSIM (physics-based simulations for molecular interaction analysis). The platform aims to dramatically accelerate drug discovery by combining machine learning with physics-based simulations to explore chemical space efficiently.

Differentiator

Problem solved

Functional benefit

Brands

• InVirtuo Platform: End-to-end AI-powered system for drug discovery combining machine learning with physics-based molecular simulations.
• InVirtuoMOL
• InVirtuoGEN
• InVirtuoSIM

Products and services

• InVirtuo Platform End-to-end AI-powered system for drug discovery that combines multimodal learning, active learning, and generative chemistry with physics-based molecular simulations. Used by pharmaceutical and biotech partners for target validation, hit discovery, lead optimization, and preclinical validation of drug candidates.
• InVirtuoGEN Open-Source Results and Pretrained Checkpoints Open-source release of the InVirtuoGEN generative chemistry model with pretrained checkpoints, benchmarks, and reproducible results on GitHub, enabling academic and developer community to validate and build on the platform's generative chemistry capabilities.

Quantifiable outcome

• 90% reduction in molecular property processing time with InVirtuoMOL
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

13 partnerships are on record, tiered major, core, flagship and supporting.

• EuroHPC JUmajorTechnology or Integration · 1 June 2026EuroHPC JU AI Large Scale Access grant providing 2,000,000 GPU-hours (worth ~€3M) on LUMI-G supercomputer to advance AI-driven search for MASH treatment.
• Helsinn Healthcare SAcoreStrategic or Co-development Partner · 25 February 2026Strategic R&D collaboration where Helsinn provides access to its proprietary library of structurally diverse compounds with confirmed biological activity against an undisclosed therapeutic target, while InVirtuoLabs applies its AI-driven generative chemistry platform InVirtuoGEN to design, optimize, and prioritize novel drug candidates for preclinical development in oncology and chronic disease indications. Collaboration aims to leverage next-generation AI technology to accelerate drug discovery and deliver therapeutic solutions to patients.
• 7hc (Italy)coreStrategic or Co-development Partner · 1 January 2026Italian partner in the €2.3 million Eurostars NEUROSPARK project focused on identifying and validating lead molecules for treating rare neurodegenerative disorders using AI-based Virtual Cell Models.
• INSYBIO (Greece)coreStrategic or Co-development Partner · 1 January 2026Greek partner in the €2.3 million Eurostars NEUROSPARK project focused on AI-based Virtual Cell Models for neurodegenerative drug research.
• oloBion (Spain)coreStrategic or Co-development Partner · 1 January 2026Spanish partner in the €2.3 million Eurostars NEUROSPARK project advancing AI-driven drug discovery for Spinocerebellar Ataxia Type 3 and broader neurodegenerative disorders.
• Innosuisse (ORION Project)flagshipStrategic or Co-development Partner · 1 September 2024Part of ORION, an Innosuisse Flagship project developing an AI-driven microfactory for patient-specific tumor models enabling personalized cancer therapies and accelerating biomarker discovery, drug development and precision oncology.
• USI Startup CentresupportingOthersIncubator location providing startup support, mentorship, and access to academic resources at Università della Svizzera Italiana in Lugano.
• NVIDIAsupportingTechnology or IntegrationTechnology supporter providing GPU computing infrastructure for AI model training and molecular simulations.
• Google CloudsupportingTechnology or IntegrationCloud infrastructure partner for AI platform deployment and computational workloads.
• Microsoft AzuresupportingTechnology or IntegrationCloud infrastructure partner for AI platform deployment and computational workloads.
• Amazon Web ServicessupportingTechnology or IntegrationCloud infrastructure partner for AI platform deployment and computational workloads.
• Swiss Startup AssociationsupportingOthersIndustry association providing startup ecosystem support and visibility.
• Fondazione AgiresupportingOthersFoundation supporting innovative startups through acceleration programs like Boldbrain.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• XtalPi: AI + physics-based drug discovery platform combining quantum physics, molecular dynamics and ML for crystal structure prediction and small molecule design. Highly comparable integrated ML + physics architecture to InVirtuoLabs' InVirtuoMOL + InVirtuoGEN + InVirtuoSIM stack.
• Atomwise: AI small molecule design company using structure-based deep learning for hit discovery and lead optimization. Directly comparable in silico-first discovery approach with pharma partnership model.
• BenevolentAI: AI drug discovery platform combining biomedical knowledge graphs with ML for target identification and drug repurposing. Comparable platform-play business model targeting pharma enterprise partnerships.
• Insilico Medicine: AI-driven drug discovery platform combining generative chemistry, target identification and deep biology. Directly comparable to InVirtuoLabs' InVirtuo Platform in combining multimodal generative AI with target-to-preclinical workflows; significantly larger and more capitalized with clinical-stage assets.
• Exscientia: AI-driven small molecule drug discovery company with platform combining generative chemistry, active learning and experimental automation. Most direct head-to-head competitor in AI-enabled end-to-end small molecule discovery, with established pharma partnerships.

Broad incumbents

• Recursion Pharmaceuticals: TechBio combining high-throughput wet-lab experimentation with ML for drug discovery. Comparable end-to-end discovery thesis to InVirtuoLabs but emphasizes experimental data generation and phenotypic screening rather than generative chemistry-first design.
• Schrödinger: Public computational chemistry and molecular simulation platform with both software and collaborative drug discovery offerings. Overlaps with InVirtuoLabs on physics-based simulation + ML, but operates at much greater scale with a broader software portfolio serving pharma across discovery and materials science.
• Isomorphic Labs: Alphabet-owned AI drug discovery company building on DeepMind's AlphaFold with end-to-end drug design capabilities. Represents the well-capitalized frontier competitor in AI-native drug discovery that InVirtuoLabs benchmarks against.

Emerging players

• Iambic Therapeutics: AI-driven drug discovery combining physics-based modeling with neural networks for small molecule design. Closely comparable technology stack and emerging-stage positioning relative to InVirtuoLabs.

Others

• ChemAxon: Cheminformatics software platform providing molecular modeling toolkits used widely in pharma drug discovery workflows. Adjacent infrastructure provider whose tools overlap with InVirtuoMOL's molecular property evaluation capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• GitHubgithub.com/invirtuolabs/InVirtuoGen_results
• LinkedInlinkedin.com/company/invirtuolabs/about/?viewAsMember=true

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InVirtuoLabs